StreetInsider.com News Articles

Bionano retires $20 million convertible debt, eliminates secured obligations

Thu, 28 May 2026 08:09:20 -0400

Bionano Genomics Inc. (NASDAQ: BNGO) announced it has fully retired and cancelled all outstanding Senior Secured Convertible Debentures worth $20 million in aggregate face value. The company used cash on hand to retire the debt instruments, which were originally issued in May 2024.

The retirement eliminates all of Bionano's secured debt obligations and releases liens on the company's assets. Associated restrictive covenants have been extinguished, according to the company's statement.

"Retiring this debt is a significant milestone for Bionano and a direct reflection of the progress we have made in strengthening and simplifying the business," said Al Luderer, chairman and interim chief

Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures

Thu, 28 May 2026 08:00:00 -0400

SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has fully retired and cancelled all outstanding Senior Secured Convertible Debentures (the "Debentures"). The Company used cash on hand to retire the Debentures, which were originally issued in May 2024 in the aggregate face value of $20,000,000.

The retirement of the Debentures completes the debt restructuring the Company undertook in May 2024 and results in Bionano carrying no outstanding secured debt obligations. With the retirement, all liens on the Company's assets are released and the associated restrictive covenants are extinguished,

Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures

Thu, 28 May 2026 08:00:00 -0400

Form 8-K Bionano Genomics, Inc. For: May 28

Thu, 28 May 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260528/26561452.html

Form 8-K Bionano Genomics, Inc. For: May 28

Thu, 28 May 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260528/26561452.html

Bionano study finds genome mapping detects 97.8% of T-cell leukemia cases

Tue, 26 May 2026 08:05:47 -0400

Bionano Genomics Inc. (NASDAQ: BNGO) announced publication of a study in Modern Pathology showing its optical genome mapping technology detected genomic abnormalities in 97.8% of T-cell acute lymphoblastic leukemia cases, compared to 55% detection by conventional cytogenetic analysis.

The study examined 91 T-ALL cases using three different analysis methods: optical genome mapping, conventional karyotyping and next-generation sequencing. Researchers from The University of Texas MD Anderson Cancer Center and Johns Hopkins University School of Medicine conducted the analysis.

The optical genome mapping technology provided additional genomic insights beyond standard methods in approximately 70% of cases. The technology detected gene rearrangements in 80% of

Bionano study finds genome mapping detects 97.8% of T-cell leukemia cases

Tue, 26 May 2026 08:05:47 -0400

The optical genome mapping technology provided additional genomic insights beyond standard methods in approximately 70% of cases. The technology detected gene rearrangements in 80% of

Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia

Tue, 26 May 2026 08:00:00 -0400

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping (OGM) detected genomic abnormalities in 97.8% of T-cell acute lymphoblastic leukemia (T-ALL) cases — nearly double the 55% detection rate achieved by conventional cytogenetic analysis. Conducted by researchers at The University of Texas MD Anderson Cancer Center and Johns Hopkins University School of Medicine and representing one of the most comprehensive genomic analyses of T-ALL to date, the study underscores OGM’s potential to transform how this aggressive blood cancer is

Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia

Tue, 26 May 2026 08:00:00 -0400

Form 4 Bionano Genomics, Inc. For: May 14 Filed by: Rajkovic Aleksandar

Thu, 14 May 2026 18:17:00 -0400

si-local-file:///var/storage/secattach/20260514/26497104.html

Form 4 Bionano Genomics, Inc. For: May 14 Filed by: Rajkovic Aleksandar

Thu, 14 May 2026 18:17:00 -0400

si-local-file:///var/storage/secattach/20260514/26497104.html

Form 4 Bionano Genomics, Inc. For: May 14 Filed by: Linney Yvonne

Thu, 14 May 2026 18:16:00 -0400

si-local-file:///var/storage/secattach/20260514/26497103.html

Form 4 Bionano Genomics, Inc. For: May 14 Filed by: Linney Yvonne

Thu, 14 May 2026 18:16:00 -0400

si-local-file:///var/storage/secattach/20260514/26497103.html

Form 4 Bionano Genomics, Inc. For: May 14 Filed by: BARKER DAVID L